News / Press Release

What Are Some of the Potential Drawbacks to Receiving an Investigational Drug?

May 13, 2017

Although investigational drugs can provide hope for cancer patients who may not be responding well to standard therapies, there are certainly drawbacks and risks associated with the opportunity. The process is associated with a whole gamut of unknowns, some of which could potentially be dangerous. Investigational drug drawbacks include the following:

Avoiding Risks With Investigational Risks

Although there’s no way to completely eliminate risks form the investigational drug equation, the protocols associated with actually obtaining said drugs can mitigate those risks. In particular, the minimum patient criteria for eligibility to receive an investigational drug can help narrow down the appropriate patient pool.

To be considered a candidate for receiving an investigational drug outside of a clinical trial drug investigation setting, physicians must establish that patients:

TD2 is a world-class drug development service that specializes in getting the most innovative oncology treatments to patients who have been let down by more traditional treatment options. We can help physicians fill out applications for patients to access investigational drugs and help doctors weigh the costs and benefits associated with a particular investigational drug for a particular patient. We can also provide information about important regulatory issues.

About Translational Drug Development (TD2)

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

About TD2

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

Contact
Tara Franks
602-358-8322
Get free tips, tools and resources by subscribing to the TD2 Newsletter: